Balancing the Risks and Benefits of Benzodiazepines
| dc.contributor.author | Hirschtritt, Matthew E. | |
| dc.contributor.author | Olfson, Mark | |
| dc.contributor.author | Kroenke, Kurt | |
| dc.contributor.department | Medicine, School of Medicine | en_US |
| dc.date.accessioned | 2022-03-25T19:42:35Z | |
| dc.date.available | 2022-03-25T19:42:35Z | |
| dc.date.issued | 2021-01 | |
| dc.description.abstract | In September 2020, the US Food and Drug Administration (FDA) announced an anticipated update to the boxed warning on all benzodiazepines to explicitly “address the serious risks of abuse, addiction, physical dependence, and withdrawal reactions” among this class of medications.1 The current boxed warning for benzodiazepines (eg, alprazolam, lorazepam, clonazepam, diazepam) highlights only the risks of coadministration of opioids and benzodiazepines. Benzodiazepines are prescribed for multiple indications, most notably generalized anxiety disorder, panic, social phobia, insomnia, and seizure prophylaxis and rescue. | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Hirschtritt, M. E., Olfson, M., & Kroenke, K. (2021). Balancing the Risks and Benefits of Benzodiazepines. JAMA, 325(4), 347–348. https://doi.org/10.1001/jama.2020.22106 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/28323 | |
| dc.language.iso | en | en_US |
| dc.publisher | AMA | en_US |
| dc.relation.isversionof | 10.1001/jama.2020.22106 | en_US |
| dc.relation.journal | JAMA | en_US |
| dc.rights | Publisher Policy | en_US |
| dc.source | Publisher | en_US |
| dc.subject | benzodiazepines | en_US |
| dc.subject | risk assessment | en_US |
| dc.subject | addiction | en_US |
| dc.title | Balancing the Risks and Benefits of Benzodiazepines | en_US |
| dc.type | Article | en_US |